AIDS Research and Therapy Pharmacology (medical)

Brief communication: clinical jaundice is associated with poor adherence to boosted atazanavir among adults in an HIV clinic in Kampala, Uganda

Angella Nabakooza, Sharon Kitibwakye Nakamanya, Eva Agnes Laker, Elizabeth Katana, Noela Owarwo, Isaac Lwanga, Barbara Castelnuovo, Mohammed Lamorde, Freddy Kitutu Eric
Springer Nature · 2026-07-04 · DOI 10.1186/s12981-026-00908-y

Abstract

Abstract Background Boosted atazanavir (ATV/r) is associated with clinical jaundice, which may affect ART adherence. However, the prevalence of clinical jaundice among people on ATV/r and its association with ART adherence is unknown in Uganda. Methods We conducted a cross-sectional study among 236 adult patients on ATV/r at the Infectious Disease Institute. Clinical jaundice was assessed by self-report and observation; ART adherence was measured using the 8-item Morisky scale. Results Period prevalence of clinical jaundice was 31.8%, while point prevalence was 21.1%. While 8.5% had poor adherence, clinical jaundice was a significant predictor of poor adherence (adjusted odds ratio = 3.03, 95% CI: 1.18–7.76, p = 0.021). Conclusion Clinical jaundice is common among patients on ATV/r in Uganda and is associated with poor ART adherence. Strengthening pre-ATV/r (pre-switch) counselling and exploring safer regimen alternatives are required to improve outcomes.

Read at publisher →